New pill aims to keep aggressive neuroendocrine cancer at bay
NCT ID NCT06926634
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether the drug zanzalintinib, taken as a maintenance therapy after initial chemotherapy, can help delay cancer progression in people with high-grade neuroendocrine neoplasms. About 32 participants will receive the drug and be monitored for how long their cancer stays under control. The goal is to see if this approach extends the time before the cancer worsens.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zanzalintinib
What this could lead to
If successful, this could provide a new maintenance option to delay cancer growth after initial chemotherapy for patients with high-grade neuroendocrine tumors.
What could go wrong
This is a small early-phase trial with only 32 participants, so results may not apply broadly. The drug may not improve survival and could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE NEUROENDOCRINE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic - Rochester
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
Contact
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact